Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model

Siebren Dijkstra, Tim M. Govers, Rianne J. Hendriks, Jack A. Schalken, Wim Van Criekinge, Leander Van Neste, Janneke P. C. Grutters, John P. Michiel Sedelaar, Inge M. van Oort*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)659-665
Number of pages7
JournalBJU International
Volume120
Issue number5
DOIs
Publication statusPublished - Nov 2017

Keywords

  • prostate cancer
  • biomarker
  • SelectMDx
  • cost-effectiveness analysis
  • prostate biopsy
  • QUALITY-OF-LIFE
  • RADICAL PROSTATECTOMY
  • HEALTH INDEX
  • FOLLOW-UP
  • BIOPSY
  • OVERDIAGNOSIS
  • OVERTREATMENT

Cite this

Dijkstra, S., Govers, T. M., Hendriks, R. J., Schalken, J. A., Van Criekinge, W., Van Neste, L., Grutters, J. P. C., Sedelaar, J. P. M., & van Oort, I. M. (2017). Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model. BJU International, 120(5), 659-665. https://doi.org/10.1111/bju.13861